{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,14]],"date-time":"2024-08-14T21:52:16Z","timestamp":1723672336176},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,2,26]],"date-time":"2011-02-26T00:00:00Z","timestamp":1298678400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ophthalmologe"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00347-010-2261-1","type":"journal-article","created":{"date-parts":[[2011,2,24]],"date-time":"2011-02-24T12:49:03Z","timestamp":1298551743000},"page":"204-212","source":"Crossref","is-referenced-by-count":5,"title":["Ein Januskopf?"],"prefix":"10.1007","volume":"108","author":[{"given":"N.","family":"St\u00fcbiger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Winterhalter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Pleyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Doycheva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Zierhut","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Deuter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,2,26]]},"reference":[{"key":"2261_CR1","first-page":"544","volume":"40","author":"Archambeau","year":"1965","unstructured":"Archambeau PL, Hollenhorst RW, Rucker CW (1965) Posterior uveitis as a manifestation of multiple sclerosis. Mayo Clin Proc 40:544\u2013551","journal-title":"Mayo Clin Proc"},{"key":"2261_CR2","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1136\/bjo.2004.061119","volume":"89","author":"Becker","year":"2005","unstructured":"Becker MD, Heiligenhaus A, Hudde T et al (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89:1254\u20131257","journal-title":"Br J Ophthalmol"},{"key":"2261_CR3","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0167-5699(96)10027-X","volume":"17","author":"Belardelli","year":"1996","unstructured":"Belardelli F, Gresser I (1996) The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17:369\u2013372","journal-title":"Immunol Today"},{"key":"2261_CR4","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/bjo.70.8.589","volume":"70","author":"BenEzra","year":"1986","unstructured":"BenEzra D, Cohen E (1986) Treatment and visual prognosis in Beh\u00e7et\u2019s disease. Br J Ophthalmol 70:589\u2013592","journal-title":"Br J Ophthalmol"},{"key":"2261_CR5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1212\/WNL.52.1.179","volume":"52","author":"Biousse","year":"1999","unstructured":"Biousse V et al (1999) Multiple sclerosis associated with uveitis in two large clinic-based series. Neurology 52(1):179\u2013181","journal-title":"Neurology"},{"key":"2261_CR6","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/bjo.2006.101550","volume":"91","author":"Bodaghi","year":"2007","unstructured":"Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrosprective monocentric study of 45 patients. Br J Ophthalmol 91:335\u2013339","journal-title":"Br J Ophthalmol"},{"key":"2261_CR7","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.ajo.2005.04.025","volume":"140","author":"Brasnu","year":"2005","unstructured":"Brasnu E, Wechsler B, Bron A et al (2005) Efficacy of interferon-alpha for the treatment of Kaposi\u2019s sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140:746\u2013748","journal-title":"Am J Ophthalmol"},{"key":"2261_CR8","doi-asserted-by":"crossref","first-page":"2237","DOI":"10.1002\/1097-0142(19900515)65:10<2237::AID-CNCR2820651013>3.0.CO;2-5","volume":"65","author":"Conlon","year":"1990","unstructured":"Conlon KC, Urba WJ, Smith JW et al (1990) Exacerbation of symptoms of autoimmune disease in patients receiving interferon-alpha therapy. Cancer 65:2237\u20132242","journal-title":"Cancer"},{"key":"2261_CR9","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1097\/01.iae.0000244265.75771.71","volume":"26","author":"Deuter","year":"2006","unstructured":"Deuter CME, K\u00f6tter I, G\u00fcnaydin I et al (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26:786\u2013791","journal-title":"Retina"},{"key":"2261_CR10","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1136\/bjo.2008.153874","volume":"93","author":"Deuter","year":"2009","unstructured":"Deuter CM, K\u00f6tter I, G\u00fcnaydin I et al (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93:906\u2013913","journal-title":"Br J Ophthalmol"},{"key":"2261_CR11","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1002\/art.27581","volume":"62","author":"Deuter","year":"2010","unstructured":"Deuter CM, Zierhut M, M\u00f6hle A et al (2010) Long-term remission after cessation of interferon-\u03b1 treatment in patients with severe uveitis due to Beh\u00e7et\u2019s disease. Arthritis Rheum 62(9):2796\u20132805","journal-title":"Arthritis Rheum"},{"key":"2261_CR12","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s00417-008-1002-5","volume":"247","author":"Doycheva","year":"2009","unstructured":"Doycheva D, Deuter CME, St\u00fcbiger N et al (2009) Interferon-alpha associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol 247:675\u2013680","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2261_CR13","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1006\/mvre.1995.1024","volume":"49","author":"Gillies","year":"1995","unstructured":"Gillies MC, Su T (1995) Interferon alpha2b enhances barrier function of bovine retinal microvascular endothelium in vitro. Microvasc Res 49:277\u2013288","journal-title":"Microvasc Res"},{"key":"2261_CR14","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/sj.thj.6200438","volume":"5","author":"Green","year":"2004","unstructured":"Green AR, Vassilou GS, Curtin N et al (2004) Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J 5:126\u2013132","journal-title":"Hematol J"},{"key":"2261_CR15","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.ajo.2008.08.038","volume":"146","author":"Gueudry","year":"2008","unstructured":"Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet\u2019s disease. Am J Ophthalmol 146:837\u2013844","journal-title":"Am J Ophthalmol"},{"key":"2261_CR16","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kem199","volume":"46","author":"Guillaume-Czitrom","year":"2007","unstructured":"Guillaume-Czitrom E, Berger C, Pajot C et al (2007) Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet\u2019s disease. Rheumatology 46:1570\u20131573","journal-title":"Rheumatology"},{"key":"2261_CR17","first-page":"928","volume":"4","author":"Hamuryudan","year":"2002","unstructured":"Hamuryudan V, Ozyazgan Y, Fresko Y et al (2002) Interferon alfa combined with azathioprine for the uveitis of Behcet\u2019s disease: an open study. Isr Med Assoc J 4:928\u2013930","journal-title":"Isr Med Assoc J"},{"key":"2261_CR18","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/ard.2007.080432","volume":"67","author":"Hatemi","year":"2008","unstructured":"Hatemi G, Bang D, Bodaghi B et al (2008) EULAR recommendations for the management of Beh\u00e7et\u2019s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 67:1656\u20131662","journal-title":"Ann Rheum Dis"},{"key":"2261_CR19","first-page":"605","volume":"8","author":"Hoffmann","year":"1994","unstructured":"Hoffmann A, Kim E, Krueger GR et al (1994) Bone marrow hypoplasia and fibrosis following interferon treatment. In Viva 8:605\u2013612","journal-title":"In Viva"},{"key":"2261_CR20","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1001\/archderm.141.7.865","volume":"141","author":"Hurst","year":"2005","unstructured":"Hurst EA, Mauro T (2005) Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 141:865\u2013868","journal-title":"Arch Dermatol"},{"key":"2261_CR21","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ICU.0b013e3282f03d42","volume":"18","author":"Imrie","year":"2007","unstructured":"Imrie FR, Dick AD (2007) Biologicals in the treatment of uveitis. Curr Opin Ophthalmol 18:481\u2013486","journal-title":"Curr Opin Ophthalmol"},{"key":"2261_CR22","first-page":"1078","volume":"335","author":"International","year":"1990","unstructured":"International Study Group for Beh\u00e7et\u2019s disease (1990) Criteria for diagnosis of Beh\u00e7et\u2019s disease. Lancet 335:1078\u20131080","journal-title":"Lancet"},{"key":"2261_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1098\/rspb.1957.0048","volume":"147","author":"Isaacs","year":"1957","unstructured":"Isaacs A, Lindemann J (1957) Viral interference. I. The interferon. Proc R Soc Lond B Biol Sci 147(927):258\u2013267","journal-title":"Proc R Soc Lond B Biol Sci"},{"key":"2261_CR24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/bjo.87.4.423","volume":"87","author":"K\u00f6tter","year":"2003","unstructured":"K\u00f6tter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Behcet\u2019s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423\u2013431","journal-title":"Br J Ophthalmol"},{"key":"2261_CR25","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.semarthrit.2003.09.010","volume":"33","author":"K\u00f6tter","year":"2004","unstructured":"K\u00f6tter I, G\u00fcnaydin I, Zierhut M et al (2004) The use of interferon alpha in Behcet\u2019s disease: review of the literature. Semin Arthritis Rheum 33:320\u2013335","journal-title":"Semin Arthritis Rheum"},{"key":"2261_CR26","first-page":"896","volume":"35","author":"Krause","year":"2008","unstructured":"Krause L, Altenburg A, Pleyer U et al (2008) Longterm visual prognosis of patients with ocular Adamantiades-Beh\u00e7et\u2019s disease treated with interferon-alfa-2a. J Rheumatol 35(5):896\u2013903","journal-title":"J Rheumatol"},{"key":"2261_CR27","doi-asserted-by":"crossref","first-page":"559","DOI":"10.2147\/OPTH.S3308","volume":"3","author":"Mackensen","year":"2009","unstructured":"Mackensen F, Regina M, Becker MD (2009) Interferons an their potential in the treatment of ocular inflammation. Clin Experiment Ophthalmol 3:559\u2013566","journal-title":"Clin Experiment Ophthalmol"},{"key":"2261_CR28","unstructured":"Mackensen F et al (2010) Long-term results of a monocentric controlled clinical trial comparing interferon beta with methotrexate in the treatment of uveitis macular edema. ARVO Abstract 2916"},{"key":"2261_CR29","first-page":"225","volume":"LXXVII","author":"Mishima","year":"1979","unstructured":"Mishima S, Masuda K, Izawa Y, Mochizuki M (1979) Beh\u00e7et\u2019s disease in Japan: Ophthalmologic aspects. Tr AM Ophth Soc LXXVII:225\u2013279","journal-title":"Tr AM Ophth Soc"},{"key":"2261_CR30","unstructured":"Montvale NJ (2000) Physicans desk reference. Medical Economics Company, Montvale, NJ, S 2654\u20132658, 2808\u20132817"},{"key":"2261_CR31","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1076\/ocii.6.4.209.4027","volume":"6","author":"Okada","year":"1998","unstructured":"Okada AA, Keino H, Fukai T (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6:209\u2013210","journal-title":"Ocul Immunol Inflamm"},{"key":"2261_CR32","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1080\/09273940590951034","volume":"13","author":"Okada","year":"2005","unstructured":"Okada AA (2005) Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13:335\u2013351","journal-title":"Ocul Immunol Inflamm"},{"key":"2261_CR33","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1517\/14712598.4.10.1609","volume":"4","author":"Okada","year":"2004","unstructured":"Okada H, Pollack IF (2004) Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4:1609\u20131620","journal-title":"Expert Opin Biol Ther"},{"key":"2261_CR34","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.1167\/iovs.06-0058","volume":"47","author":"Plskova","year":"2006","unstructured":"Plskova J, Greiner K, Muckersie E et al (2006) Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 47(9):3946\u20133950","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2261_CR35","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ajo.2007.03.050","volume":"144","author":"Plskova","year":"2007","unstructured":"Plskova J, Greiner K, Forrester JV (2007) Interferon-\u03b1 as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144(1):55\u201361","journal-title":"Am J Ophthalmol"},{"key":"2261_CR36","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1001\/archopht.1995.01100080093034","volume":"113","author":"Purvin","year":"1995","unstructured":"Purvin VA (1995) Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 113(8):1041\u20131044","journal-title":"Arch Ophthalmol"},{"key":"2261_CR37","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3949\/ccjm.71.Suppl_3.S3","volume":"71","author":"Saadeh","year":"2004","unstructured":"Saadeh S, Davis GL (2004) The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve Clin J Med 71:3\u20137","journal-title":"Cleve Clin J Med"},{"key":"2261_CR38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/09273940490518865","volume":"13","author":"Sobaci","year":"2005","unstructured":"Sobaci G, Bayraktar Z, Bayer A (2005) Interferon alpha-2a treatment for serpinginous choroiditis. Ocul Immunol Inflamm 13:59\u201366","journal-title":"Ocul Immunol Inflamm"},{"key":"2261_CR39","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/j.ophtha.2009.11.022","volume":"117","author":"Sobaci","year":"2010","unstructured":"Sobaci G, Erdem U, Durukan AH et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Beh\u00e7et\u2019s uveitis refractory to conventional treatments. Ophthalmology 117:1430\u20131435","journal-title":"Ophthalmology"},{"key":"2261_CR40","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1046\/j.1365-2893.2000.00193.x","volume":"7","author":"Saito","year":"2000","unstructured":"Saito H, Ebinuma G, Satoh H et al (2000) Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J Viral Hepat 7:64\u201374","journal-title":"J Viral Hepat"},{"key":"2261_CR41","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1586\/14737140.4.5.823","volume":"8","author":"Stoutenburg","year":"2004","unstructured":"Stoutenburg JP, Schrope B, Kaufmann HL (2004) Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther 8:823\u2013835","journal-title":"Expert Rev Anticancer Ther"},{"key":"2261_CR42","first-page":"1437","volume":"84","author":"St\u00fcbiger","year":"2000","unstructured":"St\u00fcbiger N, K\u00f6tter I, Zierhut M (2000) Complete regression of retinal neovascularisation after therapy with interferon alfa in Behcet\u2019s disease. Br J Ophthalmol 84:1437\u20131438","journal-title":"Br J Ophthalmol"},{"key":"2261_CR43","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1055\/s-2001-19687","volume":"528","author":"St\u00fcbiger","year":"2001","unstructured":"St\u00fcbiger N, K\u00f6tter I, Deuter CM et al (2001) Behcet\u2019s disease: uveitis-therapy with interferon alpha2a \u2013 prospective clinical study in 33 patients. Klin Monatsbl Augenheilkd 528:768\u2013773","journal-title":"Klin Monatsbl Augenheilkd"},{"key":"2261_CR44","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/0-306-48382-3_108","volume":"528","author":"St\u00fcbiger","year":"2003","unstructured":"St\u00fcbiger N, Crane I, K\u00f6tter I et al (2003) Interferon alpha2a in IRBP-derived peptide induced EAU \u2013 part I. Adv Exp Med Biol 528:537\u2013540","journal-title":"Adv Exp Med Biol"},{"key":"2261_CR45","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1007\/s00417-001-0425-z","volume":"240","author":"Suzuki","year":"2002","unstructured":"Suzuki J, Sakai J, Okada AA et al (2002) Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis. Graefes Arch Clin Exp Ophthalmol 240:314\u2013321","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2261_CR46","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/rheumatology\/keh311","volume":"43","author":"Treusch","year":"2004","unstructured":"Treusch M, Vonthein R, Baur M et al (2004) Influence of human recombinant interferon-alpah2a (rhIFNalpha2a) on altered lymphocyte subpopulations and monocytes in Beh\u00e7et\u2019s disease. Rheumatology 43(10):1275\u20131282","journal-title":"Rheumatology"},{"key":"2261_CR47","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00407749","volume":"278","author":"Tsambaos","year":"1986","unstructured":"Tsambaos D, Eichelberg D, Goos M (1986) Beh\u00e7et\u2019s syndrome: treatment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 278:335\u2013336","journal-title":"Arch Dermatol Res"},{"key":"2261_CR48","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1007\/s00417-006-0346-y","volume":"244","author":"Tugal-Tutgun","year":"2006","unstructured":"Tugal-Tutgun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Beh\u00e7et\u2019s uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692\u20131695","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"2261_CR49","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1001\/archophthalmol.2009.34","volume":"127","author":"Usui","year":"2009","unstructured":"Usui Y, Takeuchi M, Hattori T et al (2009) Suppression of experimental autoimmune uveoretinitis by regulatory dentritic cells in mice. Arch Ophthalmol 127:514\u2013519","journal-title":"Arch Ophthalmol"},{"key":"2261_CR50","doi-asserted-by":"crossref","unstructured":"Vandenbark AA, Huan J, Agotsch M et al (2009) Interferon-beta-1a treatment increases CD56(bright) natural killer cells and CD4+CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 215(1\u20132):125\u2013128","DOI":"10.1016\/j.jneuroim.2009.08.007"},{"key":"2261_CR51","doi-asserted-by":"crossref","first-page":"8314","DOI":"10.1158\/1078-0432.CCR-08-0705","volume":"14","author":"Wang","year":"2008","unstructured":"Wang W, Edington HD, Rao UN et al (2008) Effects of high dose IFN alpha2b on regional lymph node metastases of human melanoma: modulation of STAT5, FOXP3 and IL-17. Clin Cancer Res 14(24):8314\u20138320","journal-title":"Clin Cancer Res"},{"key":"2261_CR52","unstructured":"Yang DS, Galatowicz G, Calder VL et al (2009) Upregulation of Foxp3 expression by recombinant interferon-alpha therapy in Behcet\u2019s disease. ARVO Poster No. 1535"}],"container-title":["Der Ophthalmologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-010-2261-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00347-010-2261-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00347-010-2261-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,8]],"date-time":"2019-06-08T20:13:48Z","timestamp":1560024828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00347-010-2261-1"}},"subtitle":["Wirkungen und Nebenwirkungen der Interferontherapie in der Augenheilkunde"],"short-title":[],"issued":{"date-parts":[[2011,2,26]]},"references-count":52,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["2261"],"URL":"https:\/\/doi.org\/10.1007\/s00347-010-2261-1","relation":{},"ISSN":["0941-293X","1433-0423"],"issn-type":[{"value":"0941-293X","type":"print"},{"value":"1433-0423","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,26]]}}}